Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P.

Am J Psychiatry. 2011 Jun;168(6):603-9. doi: 10.1176/appi.ajp.2011.10081224. Epub 2011 Mar 1. Erratum in: Am J Psychiatry. 2012 Feb;169(2):223.

PMID:
21362741
2.

Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.

Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ.

J Clin Psychiatry. 2013 Jun;74(6):568-75. doi: 10.4088/JCP.12r08167. Epub 2013 Apr 19. Review.

3.

Relapse and rehospitalization: comparing oral and depot antipsychotics.

Schooler NR.

J Clin Psychiatry. 2003;64 Suppl 16:14-7. Review.

4.
5.

Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E.

Drugs. 2003;63(5):493-512. Review.

PMID:
12600227
6.

Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.

Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

Curr Med Res Opin. 2014 Aug;30(8):1643-55. doi: 10.1185/03007995.2014.915211. Epub 2014 May 2. Review.

PMID:
24730586
7.

Depot fluspirilene for schizophrenia.

Abhijnhan A, Adams CE, David A, Ozbilen M.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001718. Review.

PMID:
17253464
8.
9.

The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.

Achilla E, McCrone P.

Appl Health Econ Health Policy. 2013 Apr;11(2):95-106. doi: 10.1007/s40258-013-0016-2. Review.

PMID:
23494934
10.

[French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].

Samalin L, Abbar M, Courtet P, Guillaume S, Lancrenon S, Llorca PM.

Encephale. 2013 Dec;39 Suppl 4:189-203. doi: 10.1016/S0013-7006(13)70121-0. French.

PMID:
24373464
11.

Depot pipotiazine palmitate and undecylenate for schizophrenia.

Dinesh M, David A, Quraishi SN.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001720. Review.

PMID:
15495016
12.

Depot haloperidol decanoate for schizophrenia.

Quraishi S, David A.

Cochrane Database Syst Rev. 2000;(2):CD001361. Review.

PMID:
10796438
13.

Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Masand PS, Gupta S.

Drugs Aging. 2003;20(15):1099-110. Review.

PMID:
14651433
14.

Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.

Rauch AS, Fleischhacker WW.

CNS Drugs. 2013 Aug;27(8):637-52. doi: 10.1007/s40263-013-0083-9. Review.

PMID:
23780619
15.

[Advantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia].

Breit S, Hasler G.

Nervenarzt. 2016 Jul;87(7):719-23. doi: 10.1007/s00115-015-0021-9. Review. German.

PMID:
26597275
16.

Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery?

Harrow M, Jobe TH.

Schizophr Bull. 2013 Sep;39(5):962-5. doi: 10.1093/schbul/sbt034. Epub 2013 Mar 19. Review.

Supplemental Content

Support Center